Enliven Therapeutics, Inc.
ELVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company carries a $3.04B market cap, placing it firmly in the mid-cap category. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Market Cap
$3.04B
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-17.92
EPS (TTM)
$-1.65
EPS (Fwd)
$-2.32
ROE
-15.3%
ROA
-11.0%
Cash
$895.2M
Total Debt
$1.5M
Free CF
-$45.3M
52W Change
101.5%
Annual Financials
Cash vs Debt
Where ELVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ELVN finished 17.34% below its 150-day moving average ($46.82) and 7.28% below its 200-day moving average ($41.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELVN overbought or oversold?
At the October 20, 2026 close, ELVN's RSI(14) was 21.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $895.2M in cash and $1.5M in debt, ELVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$45.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -15.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
ELVN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ELVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.